GlassScriptPhysician profile
Fnu Shailesh
NPI 1609184480
$2,640.75
in general payments reported to CMS, 2019-2025
22 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $150 · 2021: $334 · 2022: $345 · 2023: $506 · 2024: $485 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $604.97 | 2022-2025 | |
| Heartflow, INC. | $347.01 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $324.89 | 2019-2024 | Xarelto |
| Amgen INC. | $288.81 | 2019-2024 | Repatha |
| Pfizer INC. | $265.61 | 2021-2025 | |
| Chiesi USA, INC. | $207.80 | 2020-2025 | Cleviprex, Kengreal, Juxtapid |
| Merck Sharp & Dohme LLC | $131.14 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.08 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $65.48 | 2023-2024 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals, LTD. | $36.84 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $29.44 | 2025 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.29 | 2021-2023 | Lifevest |
| Abiomed | $26.91 | 2020 | |
| Daiichi Sankyo INC. | $24.21 | 2023 | Injectafer |
| Haemonetics Corporation | $24.06 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.18 | 2024 | Wainua |
| Inari Medical, INC. | $22.62 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.98 | 2022 | |
| Akcea Therapeutics, INC. | $21.27 | 2020 | |
| Bridgebio Pharma, INC. | $18.46 | 2025 | Attruby |
| Novo Nordisk INC | $14.95 | 2023 | Wegovy |
| Gilead Sciences, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fnu Shailesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.